JP2007516292A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007516292A5 JP2007516292A5 JP2006547314A JP2006547314A JP2007516292A5 JP 2007516292 A5 JP2007516292 A5 JP 2007516292A5 JP 2006547314 A JP2006547314 A JP 2006547314A JP 2006547314 A JP2006547314 A JP 2006547314A JP 2007516292 A5 JP2007516292 A5 JP 2007516292A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- dopamine
- pharmaceutical composition
- composition according
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 34
- 239000001257 hydrogen Substances 0.000 claims 34
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- 150000002431 hydrogen Chemical class 0.000 claims 27
- 239000000442 dopamine 2 receptor blocking agent Substances 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 239000000510 dopamine 1 receptor stimulating agent Substances 0.000 claims 9
- 208000028017 Psychotic disease Diseases 0.000 claims 8
- 125000002252 acyl group Chemical group 0.000 claims 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 239000000556 agonist Substances 0.000 claims 7
- 208000012902 Nervous system disease Diseases 0.000 claims 6
- 230000000926 neurological effect Effects 0.000 claims 6
- 208000020016 psychiatric disease Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 claims 5
- 229940098778 Dopamine receptor agonist Drugs 0.000 claims 5
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 5
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 5
- 208000025966 Neurological disease Diseases 0.000 claims 4
- 229960003638 dopamine Drugs 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 3
- UXUNBLONJMOCEN-UHFFFAOYSA-N 1,2,3,4,4a,5-hexahydrobenzo[k]phenanthridine Chemical compound C1=CC=C2C=CC3=CNC(CCCC4)C4=C3C2=C1 UXUNBLONJMOCEN-UHFFFAOYSA-N 0.000 claims 3
- CFADXNKTMVZYJY-UHFFFAOYSA-N 1,2,3a,4,5,5a-hexahydrothieno[2,3-k]phenanthridine Chemical compound C1=CC=C2C3=C4CCSC4CCC3C=NC2=C1 CFADXNKTMVZYJY-UHFFFAOYSA-N 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 125000001246 bromo group Chemical group Br* 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- XLASABQETKYXNT-UHFFFAOYSA-N naphtho[1,2-h]isoquinoline Chemical class C1=CC2=CC=NC=C2C2=C1C1=CC=CC=C1C=C2 XLASABQETKYXNT-UHFFFAOYSA-N 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 206010003805 Autism Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000000164 antipsychotic agent Substances 0.000 claims 2
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 2
- -1 chloro, bromo, iodo Chemical group 0.000 claims 2
- 230000001713 cholinergic effect Effects 0.000 claims 2
- 150000008623 chromenoisoquinolines Chemical class 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 229940044601 receptor agonist Drugs 0.000 claims 2
- 239000000018 receptor agonist Substances 0.000 claims 2
- LAKYMPZFZNASFL-UHFFFAOYSA-N 12h-chromeno[2,3-h]isoquinoline Chemical compound C1=CN=CC2=C3CC4=CC=CC=C4OC3=CC=C21 LAKYMPZFZNASFL-UHFFFAOYSA-N 0.000 claims 1
- LJEGDCVWTJSBLG-UHFFFAOYSA-N 2-phenyl-1h-1-benzazepine Chemical class N1C2=CC=CC=C2C=CC=C1C1=CC=CC=C1 LJEGDCVWTJSBLG-UHFFFAOYSA-N 0.000 claims 1
- RFVXAEFIEWVAAF-UHFFFAOYSA-N 3-phenyl-1h-1,2-benzodiazepine Chemical class C1=CC2=CC=CC=C2NN=C1C1=CC=CC=C1 RFVXAEFIEWVAAF-UHFFFAOYSA-N 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims 1
- 229960004373 acetylcholine Drugs 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000002346 iodo group Chemical group I* 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000022610 schizoaffective disease Diseases 0.000 claims 1
- 0 *c1c(*)c(*)c(CN(*)[C@@]2[C@]3c4cc(O)c(*)cc4CC2)c3c1 Chemical compound *c1c(*)c(*)c(CN(*)[C@@]2[C@]3c4cc(O)c(*)cc4CC2)c3c1 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53224803P | 2003-12-23 | 2003-12-23 | |
| PCT/US2004/043145 WO2005062894A2 (en) | 2003-12-23 | 2004-12-22 | Co-administration of dopamine-receptor binding compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007516292A JP2007516292A (ja) | 2007-06-21 |
| JP2007516292A5 true JP2007516292A5 (enExample) | 2008-09-11 |
Family
ID=34738776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006547314A Withdrawn JP2007516292A (ja) | 2003-12-23 | 2004-12-22 | ドーパミン受容体結合化合物の共投与 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20070155720A1 (enExample) |
| EP (1) | EP1699450A4 (enExample) |
| JP (1) | JP2007516292A (enExample) |
| CN (1) | CN1964713A (enExample) |
| AU (1) | AU2004308413A1 (enExample) |
| CA (1) | CA2550650A1 (enExample) |
| WO (1) | WO2005062894A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2643300C (en) | 2006-02-21 | 2011-11-08 | Purdue Research Foundation | Trans-fused chromenoisoquinolines, synthesis and methods for use |
| EP2364317B1 (en) * | 2008-08-05 | 2015-07-29 | Effipharma, Inc. | Dopamine receptor ligands with enhanced duration of action |
| JP5734957B2 (ja) | 2009-04-21 | 2015-06-17 | パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | ドーパミンレセプターのオクタヒドロベンゾイソキノリンモジュレーター及びその使用 |
| CN106749018B (zh) * | 2016-11-21 | 2019-04-12 | 湖南省中药提取工程研究中心有限公司 | 一种n-甲基-2,3,7,8-四羟基苯并菲啶类化合物、制备方法和应用 |
| US10729710B2 (en) | 2017-11-24 | 2020-08-04 | H. Lundbeck A/S | Catecholamine prodrugs for use in the treatment of Parkinson's disease |
| US11168056B2 (en) | 2019-05-20 | 2021-11-09 | H. Lundbeck A/S | Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol |
| US11130775B2 (en) | 2019-05-20 | 2021-09-28 | H. Lundbeck A/S | Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11104697B2 (en) | 2019-05-20 | 2021-08-31 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11111263B2 (en) | 2019-05-20 | 2021-09-07 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| EP3972600A1 (en) | 2019-05-21 | 2022-03-30 | H. Lundbeck A/S | Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease |
| EP3972959A1 (en) | 2019-05-21 | 2022-03-30 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
| US12319710B2 (en) | 2019-05-21 | 2025-06-03 | H. Lundbeck A/S | Catecholamine prodrugs for use in the treatment of Parkinson's diseases |
| WO2020234274A1 (en) | 2019-05-21 | 2020-11-26 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047536A (en) * | 1989-03-17 | 1991-09-10 | Purdue Research Foundation | Hexahydrobenzo(A)phenanthridine compounds |
| JP3476193B2 (ja) * | 1992-05-26 | 2003-12-10 | パーデュー・リサーチ・ファウンデーション | 置換ヘキサヒドロベンゾ〔α〕フェナンスリジン類 |
| EP0690863B1 (en) * | 1993-04-06 | 2003-03-05 | Abbott Laboratories | Tetracyclic compounds as dopamine agonists |
| US5744476A (en) * | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| PT1073432E (pt) * | 1998-04-14 | 2007-10-22 | Gen Hospital Corp | Utilização da d-alanina ou da d-serina para o tratamento da esquizofrenia |
| JP4484368B2 (ja) * | 1998-10-16 | 2010-06-16 | 大日本住友製薬株式会社 | キナゾリノン誘導体 |
| AU4536599A (en) * | 1999-06-21 | 2001-01-09 | Geochemistry Research Limited | Metal-rich silica products from geothermal and synthetic aqueous systems nen wie |
| MXPA03006265A (es) * | 2001-01-16 | 2004-06-25 | Purdue Research Foundation | Metodo de tratamiento de disfuncion relacionada con dopamina mediante administracion de un agonista de receptor de dopamina d1 completo, sin generacion de tolerancia. |
| DE60323339D1 (de) * | 2002-02-15 | 2008-10-16 | Darpharma Inc | Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten |
| WO2004103263A2 (en) * | 2003-05-22 | 2004-12-02 | Yeda Research And Development Co. Ltd. | Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases |
-
2004
- 2004-12-22 AU AU2004308413A patent/AU2004308413A1/en not_active Abandoned
- 2004-12-22 EP EP04815248A patent/EP1699450A4/en not_active Withdrawn
- 2004-12-22 US US10/584,019 patent/US20070155720A1/en not_active Abandoned
- 2004-12-22 WO PCT/US2004/043145 patent/WO2005062894A2/en not_active Ceased
- 2004-12-22 CN CNA2004800418619A patent/CN1964713A/zh active Pending
- 2004-12-22 JP JP2006547314A patent/JP2007516292A/ja not_active Withdrawn
- 2004-12-22 CA CA002550650A patent/CA2550650A1/en not_active Abandoned
-
2009
- 2009-09-11 US US12/558,127 patent/US20100041690A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2216545C2 (ru) | Гетероарил-1-пиперидины и пиперазины, фармацевтическая композиция на их основе, способ лечения психозов и ослабления боли | |
| JP2007516292A5 (enExample) | ||
| JP2008513498A5 (enExample) | ||
| JP2010513434A5 (enExample) | ||
| JP2008513496A5 (enExample) | ||
| JP2005533826A5 (enExample) | ||
| CA2401502A1 (en) | Carboxylic acid derivatives as ip antagonists | |
| TWI629276B (zh) | 咪唑并嗒化合物 | |
| RU2009136592A (ru) | Терапевтические агенты | |
| RU2003115490A (ru) | Амидные производные в качестве антагонистов nmda рецептора | |
| WO2007093624A2 (en) | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin | |
| JP2008526999A5 (enExample) | ||
| JP6689856B2 (ja) | ６，７−ジヒドロピラゾロ［１，５−ａ］ピラジン−４（５Ｈ）−オン化合物およびＭＧＬＵＲ２受容体の負のアロステリック調節因子としてのそれらの使用 | |
| JP2006524662A5 (enExample) | ||
| JP2008513499A5 (enExample) | ||
| PL202473B1 (pl) | Związki stanowiące 1,3-dwupodstawione pochodne pirolidyny, sposoby otrzymywania takich związków, kompozycje zawierające takie związki oraz ich zastosowanie | |
| WO2018106916A1 (en) | Deuterated quinoxaline compounds | |
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| JP2009531434A (ja) | 痛みの治療 | |
| JP2007507494A5 (enExample) | ||
| JP2000501080A (ja) | アセチルコリン受容体の修飾因子として役立つ新規置換アリール化合物 | |
| JPWO2021053555A5 (enExample) | ||
| JP2004520289A (ja) | セロトニン作動性薬 | |
| RU2006105782A (ru) | Производные 1-сульфонилиндола, их получение и их применение в качестве лигандов 5-нт-6 | |
| RU2297420C2 (ru) | Средство против кислотоустойчивых бактерий, содержащее гетероциклические производные бензоксазина в качестве активного компонента |